Conducting clinical research studies with
SKILL, KNOWLEDGE and SAFETY.
Call to participate
860.443.4567

Posts Tagged ‘ birth control study ’

Birth Control Study

Wednesday, June 17th, 2020

 

Did you know at one time in our history animal dung was used as barrier contraception?  Did you also know in our history here in the United States up until the 1960’s it was illegal for a woman to use contraception?  We’ve come a long way.

While a variety of contraceptive products are available for a woman’s reproductive health, researchers continue to explore options for those in their reproductive years who do not wish to conceive, or who are looking to help control the sometimes painful and uncomfortable symptoms of menses.

Coastal Connecticut Research is currently conducting a clinical trial evaluating an investigational birth control product. The study is enrolling eligible women ages 18-45 years old.  Dr. Robert M. Spitz is the study gynecologist.  There is no cost to participate in the study and no cost for the investigational birth control pill which will be used by participants for one year.  Reimbursement is available to time and travel. Those wishing to learn more can text the keyword CCR to 74121 or call (860)443-4567. Email marylou@ccrstudies.com  if you have further questions. The CCRstudies team is always happy to speak with you to educate you regarding our clinical research trials and the important role of the study volunteer.

Birth Control Product Gains FDA Approval

Monday, June 1st, 2020

Exciting news!  A birth control product for use “in-the-moment,” evaluated by study participants at Coastal Connecticut Research, has gained FDA approval.  Thank you to our volunteers for participating in this women’s healthcare research study.

U.S. FDA Approves Evofem Biosciences

Phexxi TM (lactic acid, citric acid and potassium bitartrate),
the First and Only Non-Hormonal Prescription Gel for the Prevention of Pregnancy
A New Class of Female-Controlled Birth Control for Use In-The-Moment

SAN DIEGO, May 22, 2020 — Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that the U.S.
Food and Drug Administration (FDA) has approved Phexxi  TM (lactic acid, citric acid and potassium
bitartrate) vaginal gel for the prevention of pregnancy in females of reproductive potential for use as an
on-demand method of contraception.

Phexxi is the first non-hormonal, on-demand, vaginal pH regulator contraceptive designed to maintain
vaginal pH within the normal range of 3.5 to 4.5 an acidic environment that is inhospitable to sperm.
There have been a limited number of advances in birth control over the last two decades.

As the first vaginal pH regulator with a unique mechanism of action, the Company is working to have
Phexxi covered under the Affordable Care Act (ACA). The ACA mandates that private health plans provide
coverage with no out-of-pocket costs for one treatment per class in each of the classes identified by the
FDA for women in its Birth Control Guide.

Evofem is committed to ensuring access to Phexxi for all women seeking non-hormonal contraception,
including for women who are not covered by government or private health plans, and will provide a
financial assistance program to enable access for eligible women.

Taking a Chance Every Month?

Tuesday, October 3rd, 2017

Are you a sexually active woman who should be using birth control on a regular basis but isn’t?

It’s the heat of the moment and you and your partner are about to get down and funky.  You’ve been together for several years, and he flat out refuses to wear a condom, saying it doesn’t fit right. Or, if he does use a condom, he does so with a bit of complaint.  You’ve tried the pill, depo-shots, IUD’s, and the feeling of bloat, mood swings and discomfort left you feeling kind of crummy.  There have been a few months you’ve been so caught up in the excitement or romance you have neglected to use birth control.  These moments of forgetfulness can lead to a heck of a lot of responsibility 9 months down the road!

Coastal Connecticut Research in New London is conducting a birth control study testing a non-hormonal gel.  Female volunteers are needed for the study.  You will receive the investigational product at no cost. Reimbursement of up to $100 per visit is available for time and travel.  There are 5 study visits over the course of the 36 week research study period.  Dr. Robert Spitz is the local study doctor. All visits take place on Montauk Avenue in New London.

Call today to learn more!  (860) 443-4567. Speak to Kelley, our study nurse, or email marylou@ccrstudies.com.

We look forward to hearing from you today.

Nationwide Birth Control Study

Tuesday, August 22nd, 2017

Evofem Biosciences, Inc., a biotechnology company focused on the development and commercialization of women’s health products, announced the enrollment of the first patient in a Phase 3 clinical trial evaluating AMPHORA for the prevention of pregnancy.  Coastal Connecticut Research was selected by Evofem Biosciences as research site for the study. Dr. Robert M. Spitz is serving as the Primary Investigator in the study which is being conducted throughout the United States.  Research nurses include Kelley Sanok RN, Jeannine Elliott RN and Diane Palmer RN.

AMPHORA is an investigational compound being studied as a vaginal contraceptive and for the prevention of certain vaginal infections.  The local study is focusing on pregnancy prevention.  Women ages 18-35 throughout the country are participating in the study.

Coastal Connecticut Research has conducted a number of research trials pertaining to women’s healthcare and is announcing upcoming studies on stress urinary incontinence, hot flashes, and decreased sexual desire.

Those interested in learning more can contact the site at (860) 443-4567 or visit www.CCRstudies.com.  Coastal Connecticut Research is located on Montauk Avenue in New London, CT.

Non-Hormonal Birth Control

Tuesday, July 25th, 2017

Are you a woman who is looking for a different birth control option?

Coastal Connecticut Research has been involved in a variety of birth control studies over the years.  We are currently conducting the AMPOWER Clinical Research study which is testing the safety and effectiveness of a new, investigational, non-hormonal form of birth control that is to be used up to 1 hour before intercourse takes place.  The gel is believed to work by maintaining the pH of the vagina in order to prevent sperm mobility in addition to preventing sperm from reaching an egg.

Some women opt for non-hormonal contraceptive methods because they may be sensitive to the potential side effects of hormones, or perhaps they have a health history precluding their use or hormones.  Some women seeking birth control also may like the flexibility of a method such as a contraceptive gel to be used before intercourse, rather than committing to a more long term form of birth control such as an IUD or contraceptive implant.